Adagene Inc.
ADAG evidence brief
What we can confirm
- BioSniper Score:
- 6.4 / 10
- Market Cap:
- $228.3M
- Next Catalyst:
- Phase2_Topline · Jun 30, 2027
What it means
What to watch
Prepared research question
What matters most for ADAG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ADAG
Adagene Inc. (ADAG) is a clinical-stage biotechnology company leveraging its proprietary Dynamic Precision Library (DPL) platform to develop differentiated antibody therapeutics, primarily focused on oncology, with a lead candidate ADG126 (muzastotug) still in clinical development and no approved products.
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 1 catalyst for Adagene Inc..
Adagene Inc. (ADAG) is a clinical-stage biotechnology company leveraging its proprietary Dynamic Precision Library (DPL) platform to develop differentiated antibody therapeutics, primarily focused on oncology, with a lead candidate ADG126 (muzastotug) still in clinical development and no approved products.
- Cash & equivalents of $74.5M as of 2025-12-31 [sec].
- Shareholders' equity of $35.3M as of 2025-12-31 [sec].
- Accumulated deficit of US$328.8 million as of December 31, 2025 [sec · filed 2026-04-01].
- Lead product candidate ADG126 (muzastotug) is still in clinical stage; no product candidates have received marketing approval [sec · filed 2026-04-01].
- Pipeline includes wholly-owned clinical candidates ADG116, ADG126, ADG106, and ADG206, plus partnered programs with Exelixis, Third Arc Bio, and ConjugateBio [sec · filed 2026-04-01].
What works
- Proprietary Dynamic Precision Library (DPL) platform enables differentiated antibody development with precision masking technology [sec · filed 2026-04-01].
- Multiple partnered programs (Exelixis, Third Arc Bio, ConjugateBio) demonstrate scalable platform potential [sec · filed 2026-04-01].
- Wholly-owned pipeline includes four clinical-stage candidates (ADG116, ADG126, ADG106, ADG206) covering anti-CTLA-4 and anti-CD137 targets [sec · filed 2023-04-28].
What to weigh
- No product candidates have received marketing approval; all are in preclinical or clinical stages [sec · filed 2026-04-01].
- Accumulated deficit of US$328.8 million as of December 31, 2025, with expectation of continued net losses [sec · filed 2026-04-01].
- Significant additional financing likely required to fund ongoing development, which may not be available on acceptable terms [sec · filed 2026-04-01].
- Lead candidate ADG126 and others face risks of clinical trial delays, regulatory approval, and commercialization [sec · filed 2026-04-01].
From the filings
Quoted directly from source documents.
Company has no approved products and relies on clinical-stage candidates.
“we have not received marketing approval for any of our product candidates”
SEC filings · April 1, 2026
Accumulated deficit as of year-end 2025.
“As of December 31, 2025, we had accumulated deficit of US$328.8 million”
SEC filings · April 1, 2026
Proprietary platform technology.
“proprietary precision masking technology and specialized antibody engineering capabilities”
SEC filings · April 1, 2026
Catalyst timeline
- 2027-06-30 · Phase2_Topline — Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates.
Risks & what to watch (4)›
Key risks
- No approved products — All product candidates are in preclinical or clinical stages; none have received marketing approval [sec · filed 2026-04-01].
- Significant accumulated deficit — Accumulated deficit of US$328.8M as of Dec 31, 2025; net losses expected to continue [sec · filed 2026-04-01].
- Substantial additional financing needed — Company expects to need significant additional funds for R&D, trials, and potential commercialization [sec · filed 2026-04-01].
- Clinical trial and regulatory risks — Delays in enrollment, completion, or regulatory approval could materially harm business [sec · filed 2026-04-01].
What to watch
- Progress of lead candidate ADG126 (muzastotug) through clinical trials and any regulatory milestones [sec · filed 2026-04-01].
- Cash runway and ability to secure additional financing given accumulated deficit and ongoing losses [sec · filed 2026-04-01].
- Advancement of partnered programs (Exelixis, Third Arc Bio, ConjugateBio) and potential milestone payments [sec · filed 2026-04-01].
- Phase2_Topline catalyst on 2027-06-30: Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates [catalyst].
Sources: SEC filings · Generated October 3, 2026 · How we verify sources →
Run Adagene Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Adagene Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.75
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~258d
3 buys · 0 sells (180d)
Catalysts
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
25
Total value held
$9.7M
| Holder | Shares | Value |
|---|---|---|
| exome asset management llc | 736,845 | $2.9M |
| ameriprise financial inc | 607,903 | $2.4M |
| hsg holding ltd | 1,343,364 | $2.0M |
| mill creek capital advisors, llc | 199,610 | $782K |
| morgan stanley | 66,148 | $259K |
| invesco ltd. | 47,124 | $185K |
| smartharvest portfolios, llc | 40,312 | $158K |
| kamunting street capital management, l.p. | 38,070 | $149K |
| persistent asset partners ltd | 35,126 | $138K |
| dauntless investment group, llc | 34,775 | $136K |
Showing top 10 of 25 institutional holders of Adagene Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 0.2%
- Days to cover
- 0.3
- Shares short
- 71,244
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ADAG short interestFrequently asked questions
What is the AI investment thesis for Adagene Inc.?
Adagene Inc. (ADAG) is a clinical-stage biotechnology company leveraging its proprietary Dynamic Precision Library (DPL) platform to develop differentiated antibody therapeutics, primarily focused on oncology, with a lead candidate ADG126 (muzastotug) still in clinical development and no approved products.
What is Adagene Inc.'s next catalyst?
Adagene Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase2_Topline: Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates" — expected June 30, 2027.
Who is the CEO of Adagene Inc.?
Dr. Peter P. Luo Ph.D. is the chief executive officer of Adagene Inc. (ADAG).
Where is Adagene Inc. headquartered?
Adagene Inc. (ADAG) is headquartered in Suzhou, China.
What therapeutic areas does Adagene Inc. focus on?
Adagene Inc. develops therapies across Oncology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.